{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:39:29Z","timestamp":1777480769896,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2023,11,20]]},"abstract":"<jats:p>BACKGROUND: The response of Renal Cell Cancer (RCC) to tyrosine kinase inhibitors (TKI) has been well established. Although these stratifications have been established for TKI response and prognosis, these parameters have recently been used to predict immunotherapy response in RCC. We aimed to use a combination of clinical parameters of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups and metastatic sites at the time of diagnosis to predict the effectiveness of immune checkpoint inhibitors in malignant melanoma (MM). METHOD: In this cross-sectional study, we retrospectively analyzed the demographic information, metastatic sites, and IMDC risk group data. The blood parameters were included in the first cycle of nivolumab treatment. RESULTS: The OS was statistically different between the RCC and MM groups in terms of the IMDC. In univariate analysis of stage at diagnosis, CRP levels and bone and bone marrow metastases were confirmed to be prognostic factors in the MM population in terms of OS. Brain metastasis was a prognostic factor for RCC, whereas sex, line of treatment, LDH, bone, and splenic metastasis remained significant in patients with MM in terms of OS. Brain metastasis was prognostic in both cancer types in multivariate analysis in terms of PFS. In addition to brain metastasis, LDH levels and lung, liver, and splenic metastases also affect PFS in patients with MM undergoing nivolumab treatment. CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.<\/jats:p>","DOI":"10.3233\/cbm-230159","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:12:39Z","timestamp":1694776359000},"page":"367-377","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0853-4096","authenticated-orcid":false,"given":"Ismail","family":"Beyp\u0131nar","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Alanya Alaaddin Keykubat University, Alanya\/Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-7309","authenticated-orcid":false,"given":"Y\u0131ld\u0131z","family":"S\u00f6zel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Antalya Research and Education Hospital, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-5228","authenticated-orcid":false,"given":"Arif Hakan","family":"\u00d6nder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Research and Education Hospital, Antalya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-230159_ref1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.3233\/CBM-230159_ref2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, Inflammation, and Cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell."},{"key":"10.3233\/CBM-230159_ref3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2007.02.001","article-title":"Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes","volume":"19","author":"Bui","year":"2007","journal-title":"Curr Opin Immunol."},{"key":"10.3233\/CBM-230159_ref4","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","article-title":"Tumor associated macrophages and neutrophils in cancer","volume":"218","author":"Galdiero","year":"2013","journal-title":"Immunobiology."},{"key":"10.3233\/CBM-230159_ref5","doi-asserted-by":"crossref","unstructured":"A.J. Templeton, M.G. McNamara, B. \u0160eruga, F.E. Vera-Badillo, P. Aneja, A. Oca\u00f1a, R. Leibowitz-Amit, G. Sonpavde, J.J. Knox, B. Tran, I.F. Tannock and E. Amir, Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis, J Natl Cancer Inst. 106 (2014).","DOI":"10.1093\/jnci\/dju124"},{"key":"10.3233\/CBM-230159_ref6","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.3233\/CBM-230159_ref7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.3233\/CBM-230159_ref8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med."},{"key":"10.3233\/CBM-230159_ref9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"key":"10.3233\/CBM-230159_ref10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"key":"10.3233\/CBM-230159_ref11","first-page":"1","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer 2021 201."},{"key":"10.3233\/CBM-230159_ref12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40425-017-0283-9","article-title":"The immune system in cancer metastasis: friend or foe?","volume":"5","author":"Janssen","year":"2017","journal-title":"J Immunother Cancer."},{"key":"10.3233\/CBM-230159_ref13","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients","volume":"112","author":"Ferrucci","year":"2015","journal-title":"Br J Cancer."},{"key":"10.3233\/CBM-230159_ref14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.juro.2008.04.025","article-title":"Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy","volume":"180","author":"Tatokoro","year":"2008","journal-title":"J Urol."},{"key":"10.3233\/CBM-230159_ref15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","article-title":"Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer."},{"key":"10.3233\/CBM-230159_ref16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"10.3233\/CBM-230159_ref17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cam4.2024","article-title":"Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med."},{"key":"10.3233\/CBM-230159_ref18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.bjc.6604218","article-title":"Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience","volume":"98","author":"Arkenau","year":"2008","journal-title":"Br J Cancer."},{"key":"10.3233\/CBM-230159_ref19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.26413","article-title":"Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center","volume":"118","author":"Garrido-Laguna","year":"2012","journal-title":"Cancer."},{"key":"10.3233\/CBM-230159_ref20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.bjc.6601038","article-title":"Prognostic factors for patients with hepatic metastases from breast cancer","volume":"89","author":"Wyld","year":"2003","journal-title":"Br J Cancer."},{"key":"10.3233\/CBM-230159_ref21","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.3233\/CBM-230159_ref22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet."},{"key":"10.3233\/CBM-230159_ref25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","article-title":"The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer","volume":"75","author":"van Dijk","year":"2019","journal-title":"Eur Urol."},{"key":"10.3233\/CBM-230159_ref26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","article-title":"Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab","volume":"13","author":"Tanizaki","year":"2018","journal-title":"J Thorac Oncol."},{"key":"10.3233\/CBM-230159_ref27","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00262-020-02637-1","article-title":"Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab","volume":"69","author":"Simonaggio","year":"2020","journal-title":"Cancer Immunol Immunother."},{"key":"10.3233\/CBM-230159_ref28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cam4.1356","article-title":"Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma","volume":"7","author":"Rosner","year":"2018","journal-title":"Cancer Med."},{"key":"10.3233\/CBM-230159_ref29","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1136\/jitc-2021-002851","article-title":"Original research: Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.3233\/CBM-230159_ref30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.21873\/anticanres.14913","article-title":"Site-specific Response to Nivolumab in Renal Cell Carcinoma","volume":"41","author":"Negishi","year":"2021","journal-title":"Anticancer Res."},{"key":"10.3233\/CBM-230159_ref31","doi-asserted-by":"crossref","unstructured":"M. Tamiya, A. Tamiya, T. Inoue, M. Kimura, K. Kunimasa, K. Nakahama, Y. Taniguchi, T. Shiroyama, S. ichi Isa, K. Nishino, T. Kumagai, H. Suzuki, T. Hirashima, S. Atagi and F. Imamura, Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial, PLoS One. 13 (2018).","DOI":"10.1371\/journal.pone.0192227"},{"key":"10.3233\/CBM-230159_ref32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-017-3444-0","article-title":"Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.","volume":"80","author":"Nomura","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.3233\/CBM-230159_ref33","doi-asserted-by":"crossref","unstructured":"J. Hofbauer, A. Hauck, C. Matos, N. Babl, S.M. Decking, M. Rechenmacher, C. Schulz, S. Regotta, M. Mickler, S. Haferkamp, P.J. Siska, W. Herr, K. Renner, M. Kreutz and A. Schnell, Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy, Biomolecules. 12 (2022).","DOI":"10.3390\/biom12050716"},{"key":"10.3233\/CBM-230159_ref34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5582\/bst.2018.01158","article-title":"Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab","volume":"12","author":"Okuhira","year":"2018","journal-title":"Biosci Trends."},{"key":"10.3233\/CBM-230159_ref35","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget."},{"key":"10.3233\/CBM-230159_ref36","doi-asserted-by":"crossref","unstructured":"M.A. Bilen, J.M. Shabto, D.J. Martini, Y. Liu, C. Lewis, H. Collins, M. Akce, H. Kissick, B.C. Carthon, W.L. Shaib, O.B. Alese, C.E. Steuer, C. Wu, D.H. Lawson, R. Kudchadkar, V.A. Master, B. El-Rayes, S.S. Ramalingam, T.K. Owonikoko and R.D. Harvey, Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy, BMC Cancer. 19 (2019).","DOI":"10.1186\/s12885-019-6073-7"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-230159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:10:26Z","timestamp":1777385426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/CBM-230159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":34,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/cbm-230159","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}